Objectives: Resistance to the fluoroquinolone drug ciprofloxacin is commonly linked to mutations that alter the drug target or increase drug efflux via the major AcrAB-TolC transporter. Very little is known about other mutations that might also reduce susceptibility to ciprofloxacin. We discovered that an Escherichia coli strain experimentally evolved for resistance to ciprofloxacin had acquired a mutation in rpoB, the gene coding for the b-subunit of RNA polymerase. The aim of this work was to determine whether this mutation, and other mutations in rpoB, contribute to ciprofloxacin resistance and, if so, by which mechanism.
Introduction
Ciprofloxacin is an important broad-spectrum antibacterial drug, employed to treat a wide variety of infections in human medicine, including urinary tract infections. 1, 2 Resistance to ciprofloxacin has been increasing, 3, 4 making it important to understand as fully as possible the genetic mechanisms that can contribute to reducing susceptibility. Escherichia coli, the most common cause of urinary tract infections, is naturally susceptible to ciprofloxacin (most frequent WT MIC 0.016 mg/L 5 ), but resistance mutations and horizontally acquired resistance determinants can individually increase the MIC by a factor of 2-20. 6 -8 There are no single genetic alterations that can raise the MIC above the clinical breakpoint (1 mg/L). 9 Thus, the evolution of resistance to ciprofloxacin in E. coli always involves a multistep process, with each individual genetic alteration contributing to increase the MIC before the breakpoint is exceeded. 7 Known mutations in E. coli that increase the MIC of ciprofloxacin fall into two classes: (i) those that alter the primary and secondary drug target genes [gyrA and gyrB (DNA gyrase) and parC and parE (DNA topoisomerase IV)]; and (ii) those that decrease the intracellular concentration of the drug, usually by mutation of genes encoding regulators of drug efflux (marR, acrR and soxR). 10 Recently, after experimentally evolving E. coli MG1655 in the presence of ciprofloxacin to the clinical resistance breakpoint, we discovered by WGS that the strain had acquired not only target and efflux mutations, but also a mutation in rpoB. In this study, our aim was to determine whether mutations in rpoB contribute to ciprofloxacin resistance. As reported here, we could show that mutations in rpoB frequently arise under selection with ciprofloxacin and that they can contribute to the resistance phenotype by increasing the expression level of an efflux pump that is capable of exporting ciprofloxacin. Accordingly, this study identifies mutations in RNA polymerase as a new class contributing to the development of resistance to this fluoroquinolone drug.
Materials and methods

Bacterial strains and growth conditions
All strains used in this study are derived from the WT E. coli K12 strain MG1655. 11 Bacteria were grown in liquid Luria broth medium or on solid Luria agar (Luria broth with 1.5% agar; Oxoid, Basingstoke, UK) at 378C. Mueller -Hinton agar (Difco Becton Dickson, MD, USA) was used for MIC determinations. Exponential growth rates were measured using a Bioscreen C (Oy Growth Curves, Finland) and calculated from the rate of increase in OD as a function of time.
Antibiotics
Antibiotics for liquid and solid media were purchased from Sigma-Aldrich (Stockholm, Sweden) and used at the following final concentrations: tetracycline, 15 mg/L, or 50 mg/L for strains with efflux mutations; kanamycin, 50 mg/L; chloramphenicol, 40 mg/L, or 80 mg/L for strains with efflux mutations; rifampicin, 100 mg/L; and ciprofloxacin, dissolved in water at a concentration of 1 mg/mL and diluted immediately prior to use in Luria broth at the concentrations stated in the text.
Evolution of resistance to ciprofloxacin in liquid culture
Independent lineages of MG1655 were initiated by picking separate colonies from Luria agar, inoculating each into 2 mL of Luria broth in 15 mL tubes and growing with shaking at 378C overnight. After overnight incubation, 100 mL of each culture was transferred into 2 mL of Luria broth medium containing 0.016 mg/L ciprofloxacin (approximately the MIC for MG1655) and grown overnight. Each successive day, 100 mL of each culture (population transfer bottleneck of 2×10 8 cfu) was inoculated into 2 mL of fresh medium in which the drug concentration had been increased 1.5-fold relative to the previous concentration. Selection was continued for 16 growth cycles until a final drug concentration of 3 mg/L. The remainder of each culture was stocked at 2808C after each cycling step.
WGS
Genomic DNA was prepared using the Genomic DNA Buffer Set (Qiagen, Sweden) and sent to BGI (Tai Po, Hong Kong) for library assembly and genome sequencing. Sequencing data were aligned and analysed using the CLC Genomic Workbench 6 program (CLC bio, Denmark). All putative mutations were confirmed by local resequencing.
Local DNA sequencing
Local DNA sequencing of PCR-amplified DNA was performed at Macrogen Europe (Amsterdam, The Netherlands) and data were analysed using CLC Main Workbench 6.
PCR
The oligonucleotide primers used for PCR amplification and DNA sequencing are listed in Table S1 (available as Supplementary data at JAC Online). Recombineering cassettes were amplified using Phusion w High-Fidelity PCR Master Mix with HF Buffer (New England Biolabs, Ipswich, MA, USA). All other PCRs were performed using Fermentas PCR Master Mix (2×) (Thermo Scientific, Waltham, MA, USA).
Strain constructions
Mutations, including drug resistance cassettes, were introduced into the E. coli chromosome by l-Red recombineering 12 using the pSIM5-tet plasmid 13 and moved between strains by P1 virA-mediated transduction. DNA cassettes of cat-sacB or kan-sacB were amplified by PCR from laboratory collection strains CH1900 or CH1991, respectively. Single-stranded oligonucleotides for electroporation were dissolved in water at 100 ng/mL. Electroporation was performed using a Gene Pulser TM (Bio-Rad Laboratories) on a mixture of 50 mL of electrocompetent cell culture and 100 ng of the recombineering cassette. Removal of cassettes by counterselection was done as described in Ellis et al., 12 by induction of l-Red followed by electroporation with a 'repair oligonucleotide' with homology to chromosomal sequences flanking the cassette and selection on an appropriate medium. All genetic modifications were confirmed by DNA sequencing.
MIC determinations
MICs of antibiotics were determined using Etest strips (bioMé rieux, Marcy-l'É toile, France) and M.I.C.Evaluator strips (Thermo Scientific) on Mueller -Hinton agar according to the manufacturers' instructions. For each strain, five independent MIC tests were performed and a MannWhitney U-test was conducted to test for significant changes in the MIC. All values are shown as the median value.
Competition experiments
Isogenic strains carrying different fluorescent markers, bfp or yfp, inserted into the galK gene (galK::mTagBFP2-kan and galK::SYFP2-kan) were used in competition experiments. The strains were grown separately overnight in Luria broth, mixed 1 :1 and then diluted 1000-fold in the medium used for growth competition. Each competition was made in Luria broth with a range of ciprofloxacin concentrations in the range 0.01 -1× MIC for the more susceptible strain of each competing pair. These concentrations were chosen to mimic the drug selective conditions under which each new mutation was selected during lineage evolution. The mixed cultures were diluted 1000-fold every 24 h for 3 days (resulting in 10 generations of net growth per serial passage). The change in the ratio of each strain as a function of time was determined using a fluorescence-activated cell sorter (BD FacsAria), counting 10 5 cells at each serial passage. Each competition was measured in five independent replicate cultures. Selection coefficients were calculated as described previously. 14 
Preparation of RNA and quantitative real-time PCR
Strains to be assayed were grown in Luria broth until mid-exponential phase. Aliquots of 1500 mL of the culture were added to 3 mL of RNAprotect Bacteria Reagent (Qiagen). Using the RNeasy Mini Kit (Qiagen), total RNA was isolated according to the manufacturer's protocols. The quality of the RNA was assayed by gel electrophoresis and the concentration of the samples was measured using a Nanodrop NO-1000 spectrophotometer. To remove chromosomal DNA from the RNA preparations, the DNase Turbo DNA-free kit (Ambion, Life Technologies) was used. RNA (500 ng) was converted into cDNA using the High Capacity Reverse Transcription kit (Applied Biosystems), total reaction volume of 50 mL. The thermal steps were 10 min at 258C and 2 h at 378C. For quantitative real-time PCR, 2.5 mL of cDNA (diluted 1 : 10, 1 : 100 and 1 : 1000), 5 mL of PerfeCTa SYBR Green FastMix (Quanta BioSciences), 0.625 mL of 6 mM forward and reverse primers (to a final concentration of 0.375 mM) and ddH 2 O were added to give a final reaction volume of 10 mL. The Eco Real-Time PCR System (Illumina) was used for running the PCR. Amplification of the cysG and hcaT genes was used as standard. The oligonucleotides used as quantitative RT-PCR primers are listed in Table S1 .
RNA sequencing
Strains for RNA sequencing were prepared in duplicate. Bacterial cultures were grown to mid-log phase and 3 mL of each culture was treated with 6 mL of RNAprotect Bacteria Reagent (Qiagen). Treated cultures were pelleted by centrifugation and cell pellets were sent to BGI for transcriptome analysis (Tai Po, Hong Kong). RNA sequencing data were analysed using the CLC Genomic Workbench 6 program (CLC bio, Denmark). Fold change of the expression values was calculated using the Empirical Analysis of DGE tool, which is an implementation of the Exact Test in the EdgeR Pietsch et al. Table S2 .
Results
RNA polymerase mutations occur frequently during the selection for ciprofloxacin resistance
In an initial study, we evolved E. coli MG1655 in stepwise increasing concentrations of ciprofloxacin up to 3 mg/L (see the Materials and methods section). Genetic analysis revealed that in addition to acquiring mutations in known resistance-associated genes (gyrA, marR and acrR), a mutation had also occurred in rpoB, namely rpoB E1279G. This mutation was located outside the rifampicin resistance-determining region (RRDR) of rpoB and had only a small effect on the rifampicin MIC (WT 12 mg/L, mutant 32 mg/L) compared with the increase caused by classical Rif R mutations, which increase the MIC .100-fold, from 12 up to 1500 -3000 mg/L. 15 -17 To address the potential significance of this unusual rpoB mutation, we repeated the evolution experiment and asked whether the selection of mutations in rpoB was a frequent event under selection with ciprofloxacin. Ten independent lineages of MG1655 were evolved in Luria broth with selection for ability to grow in increasing concentrations of ciprofloxacin as described in the Materials and methods section. At least 20 clones from each of the 10 endpoint cultures were assayed by local DNA sequencing for the presence of mutations in rpoB. In 3 of the 10 endpoint cultures, 20% -30% of the clones sequenced carried a mutation in rpoB, namely rpoB D442 -445 (28% in lineage 1), rpoB Dup S455 (30% in lineage 2) and rpoB A1277V (20% in lineage 9). As observed in the initial study, each of these three rpoB mutations mapped outside the RRDR and the evolved strains had a minor increase in the rifampicin MIC [WT 12 mg/L, lineage 1 (rpoB D442 -445) 48 mg/L, lineage 2 (rpoB Dup S455) 72 mg/L and lineage 9 (rpoB A1277V) 32 mg/L]. Individual clones carrying rpoB mutations from each of the three lineages were wholegenome sequenced. WGS analysis revealed that each of the three clones carried a total of four to five mutations (Table 1) , including mutations in the genes encoding the primary drug target DNA gyrase (gyrA and gyrB) and mutations in genes coding for repressors that regulate the expression of the AcrAB-TolC drug efflux system (marR, acrR and soxR).
We concluded that rpoB mutations occurred frequently during the selection for ciprofloxacin resistance and chose the three sequenced clones for additional functional studies into the significance of the ciprofloxacin-selected mutations in rpoB.
Development of ciprofloxacin resistance follows a predictable evolutionary trajectory
We first determined the temporal order of appearance of each of the mutations identified in the three sequenced clones that carried rpoB mutations. Clones from cultures that had been stored at earlier steps in the evolution of each lineage were analysed by PCR and local sequencing of genes identified by WGS. In this way, we determined that the rpoB mutations arose relatively late in the evolution of each strain, as either the third or fourth acquired mutation (Table 1) . In each strain, the general order of mutational occurrence was: first, target mutation(s) in gyrA or gyrA and gyrB; second, mutation of an efflux regulator; and third, mutation in rpoB. In two of the three strains, an additional target or efflux-associated mutation arose after the rpoB mutation (Table 1 ). In the course of screening clones from cultures at earlier steps in the evolution, we also identified strains in lineages 1 and 9 that carried alternative rpoB mutations (rpoB E1272G in lineage 1 and rpoB H1244L in lineage 9). Thus, a total of six different mutations were identified in rpoB during selection with ciprofloxacin. All mutations mapped outside the RRDR and clustered in two regions of the gene and protein ( Figure 1 ).
Based on this temporal information, we constructed three sets of isogenic strains that represent each successive step in the evolutionary trajectories of the three lineages and determined the MIC of ciprofloxacin (Table 2) . If the deduced order is correct, it is expected that the MIC of ciprofloxacin should increase with the addition of each successive mutation. This was shown to be the case for each of the reconstructed strains for all three lineages and the final ciprofloxacin MIC for the constructed strains matched in each case the ciprofloxacin MIC for the evolved strain (Table 2 ). In all three lineages, the addition of the ciprofloxacinselected rpoB mutation increased the MIC from 0.375 mg/L (25-fold WT MIC) up to 1 mg/L (rpoB Dup S455, 67-fold WT MIC) and 1.5 mg/L (rpoB D442 -445 and rpoB A1277V, 100-fold WT MIC). This magnitude of the fold increase in the ciprofloxacin MIC caused by these rpoB mutations is at least as great as that Ciprofloxacin selects RNA polymerase mutations JAC caused by resistance mutations that inactivate efflux pump regulators. 7 Next, we determined the MIC of rifampicin for each of the reconstructed strains to test if the increase in the MIC of rifampicin coincided with the presence of the rpoB mutations. As expected, each of the three ciprofloxacin-selected rpoB mutations was responsible for an increase in the rifampicin MIC (from 12 up to 32 -72 mg/L; Table 2 ), far below the values of 1500 -3000 mg/L associated with classical Rif R mutations in E. coli.
15,18
We concluded that the development of ciprofloxacin resistance followed a predictable pattern, in which rpoB mutations appeared in the third mutational wave. The selected rpoB mutations are located outside the RRDR and confer only a modest increase in rifampicin resistance.
Ciprofloxacin-selected rpoB mutations confer a competitive advantage in the presence of ciprofloxacin
In a previous study, we showed that different rpoB mutations, selected for resistance to rifampicin, had different effects on the growth rate, from nearly cost-free to nearly lethal. 18 To test the effect that the rpoB mutations selected for ciprofloxacin resistance have on bacterial fitness, we measured the exponential growth rates of the set of strains representing each step in the evolution of the three isolated clones ( Table 2 ). The data showed no dramatic change in growth rate associated with the acquisition of the initial mutations affecting the drug target and drug efflux regulation. However, in each case the addition of a mutation in rpoB caused a large reduction in the growth rate (Table 2) .
These data suggested that the mutants carrying these rpoB mutations should be strongly counterselected, unless their fitness costs were counterbalanced by the selective advantage they potentially confer when ciprofloxacin is present in the growth environment. We tested this hypothesis by competing the isogenic strains pairwise in the presence of different concentrations of ciprofloxacin. Growth competition assays were performed on consecutive pairs of strains, representing the temporal order of mutation acquisition during the evolution of each lineage, and in the presence of a range of ciprofloxacin concentrations (see the Materials and methods section). The data (Figure 2 and Figures S1-S3) show that for each strain pair, the acquisition of an additional mutation provided a competitive advantage as the concentration of ciprofloxacin approached the MIC for the 'parental' strain. This advantage was apparent regardless of the cost of the additional mutation in the absence of drug (Figure 2 and Figures S1-S3). These competitions identified, for each strain pair, the minimum selective concentration (MSC) of drug at which the successor strain outcompetes the prior strain and becomes enriched in the mixed population. For each additional mutation, the MSC successively increased, further confirming the deduced evolutionary trajectory. In conclusion, the competition experiments show that under the conditions in which each lineage was evolved, there was a selective advantage conferred by the acquisition of each successive mutation, including for the rpoB alleles. Pietsch et al.
Ciprofloxacin-selected rpoB mutations are functionally distinct from rifampicin-selected rpoB mutations
During the evolution of ciprofloxacin resistance, we isolated six distinct rpoB mutations that cluster into two regions of RNA polymerase that are structurally distant to the RRDR. Nevertheless, the ciprofloxacin-selected rpoB mutations did cause a minor increase in the MIC of rifampicin, suggesting that there might be a functional overlap between ciprofloxacin-selected and rifampicinselected rpoB mutations. To determine how different rpoB mutations affect ciprofloxacin resistance, we inserted a variety of rpoB mutations into a set of four strains with different genetic backgrounds. The four different backgrounds tested were WT E. coli and the three strains selected during evolution at the step before the rpoB mutations appeared. The rpoB mutations tested consisted of the six ciprofloxacin-selected rpoB mutations identified in this study and four rifampicin-selected rpoB mutations. In total, 40 distinct strains (24 ciprofloxacin-selected and 16 rifampicin-selected) were constructed and the ciprofloxacin MIC was determined for each of the strains (Table 3) . First, our results showed that all ciprofloxacin-selected rpoB mutations increased the ciprofloxacin MIC even in the absence of any additional mutation (Table 3 ). This showed that the ciprofloxacin-selected rpoB mutations are not dependent on other resistance mutations to decrease the susceptibility to ciprofloxacin. Furthermore, all the ciprofloxacin-selected rpoB mutations were functionally interchangeable, such that each of the six mutations increased the ciprofloxacin MIC when inserted into any one of the three evolutionary backgrounds. In total, the ciprofloxacin MIC, as determined by five independent MIC tests for each of the strains, was significantly increased for all 24 combinations tested. In contrast, only two of the rifampicin-selected rpoB mutations increased the ciprofloxacin MIC and this effect was significant in only 4 out of 16 combinations tested. We concluded that the two groups of rpoB alleles overlap to some extent, but that ciprofloxacin-selected rpoB mutations are in general functionally distinct from the rifampicin-selected rpoB mutations.
Ciprofloxacin-selected rpoB mutations increase expression of the multidrug efflux pump MdtK
It is expected that mutations in rpoB could alter global transcription patterns by changing promoter recognition and binding stability. 19 -21 A change in the global transcription pattern might influence ciprofloxacin susceptibility in at least two distinct ways. It was previously observed in Staphylococcus aureus that a point mutation located upstream of the start codon of parE reduced gene expression (topoisomerase IV is the primary target in S. aureus) and thereby caused reduced fluoroquinolone Ciprofloxacin selects RNA polymerase mutations JAC susceptibility. 22 Accordingly, one possibility to explain the phenotype of ciprofloxacin-selected mutations in rpoB is that they affect transcription so as to reduce the expression level of the drug target, DNA gyrase. Another possibility is that the rpoB mutations increase expression of one or more efflux pumps that can export ciprofloxacin.
To assess the global transcription patterns in our polymerase mutant strains and detect possible changes in RNA levels caused by mutant RNA polymerase, we decided to conduct transcriptome analysis on two of the ciprofloxacin-selected rpoB mutants. We chose the two strains conferring the highest increase in the ciprofloxacin MIC for isogenic WT strains with mutations in rpoB located in cluster I (rpoB D442-445 and rpoB Dup S455). To recapitulate the influence of the rpoB mutations on the transcriptional pattern during the evolution of ciprofloxacin resistance, we compared expression levels between the two strains representing the evolutionary steps before and after the acquisition of the rpoB mutation.
The two rpoB mutations used in the expression analyses are located in the same region of RNA polymerase ( Figure 1 ) and are therefore expected to alter the global expression pattern in a comparable fashion. A comparison of the changes in expression levels caused by these two rpoB mutations showed strong correlation (P, 10 216 ), confirming this hypothesis (Table S2 and Figure S4 ). In total, 106 genes were significantly up-or downregulated by both rpoB mutations. Mutations in a few of these genes have previously been shown to affect the level of susceptibility to other antibiotics: lamB (down-regulated), deletion increases the MIC of tetracycline; 23 and rimK and rplF (downregulated), mutations can increase the MIC of kanamycin. 24, 25 The expression analyses showed no changes in the mRNA levels of the drug targets DNA gyrase (gyrA and gyrB) and topoisomerase IV (parC and parE). We conclude that the ciprofloxacinselected rpoB mutations do not cause a reduction in the level of drug target transcripts and, thus, that there is no evidence to support a reduction in the level of target enzyme as a mechanism for the reduced susceptibility to ciprofloxacin. Next, we asked whether the rpoB mutations could increase efflux pump expression. The AcrAB-TolC efflux pump (acrA, acrB and tolC) is the major efflux system associated with reduced susceptibility to ciprofloxacin. We found no change in the mRNA levels of any of the three efflux pump components. However, analysis of the RNA sequencing data revealed that mdtK, encoding the MATE family multidrug transporter MdtK, 26, 27 showed a 4-to 6-fold increased transcript level for both rpoB mutations (Table S2) . There was no significant change in expression level associated with any other gene that has previously been associated with Pietsch et al.
resistance or susceptibility to ciprofloxacin (Table S2) . We used quantitative RT -PCR to confirm the increased expression of mdtK in the two rpoB mutant strains and found that in both strains, mdtK mRNA levels were increased 3-to 4-fold (Figure 3) .
To examine if the overexpression of MdtK is responsible for the decreased susceptibility to ciprofloxacin in the evolved strains that carried the rpoB mutations, we first asked whether MdtK contributes to the ciprofloxacin MIC at the step in evolution before the acquisition of the rpoB mutations. To test this, we deleted the mdtK gene from these strains and did not observe any change in the ciprofloxacin MIC (Table 4 ). This confirms that MdtK does not contribute to the reduced susceptibility to ciprofloxacin at that stage. Next, we cloned the mdtK gene into a plasmid and asked if overexpression of MdtK could affect the ciprofloxacin MIC for these strains. As expected, susceptibility to ciprofloxacin was reduced. The effect of overexpressing MdtK on the ciprofloxacin MIC was similar to the effect of acquiring one of the rpoB mutations (Table 4 ).
Finally, we tested if MdtK contributed to the ciprofloxacin MIC for the strains that carried the rpoB mutations. To test this, we deleted the mdtK gene from the evolved strains at the step in evolution after the acquisition of the rpoB mutations and assayed the ciprofloxacin MIC. We were able to show that the ciprofloxacin MIC was reduced in the absence of the mdtK gene (Table 4) . To further confirm this, we did pairwise competitions between evolved rpoB mutant strains and their respective mdtK knockouts in the presence of different ciprofloxacin concentrations. As predicted, strains carrying an intact mdtK gene had a significant advantage over their competitors (Figure 4 ). These data support the hypothesis that the selected rpoB mutations cause an overexpression of MdtK, which in turn causes decreased drug susceptibility.
The data in Table 4 suggest that overexpression of mdtK accounts for most, but not all, of the increase in the ciprofloxacin MIC caused by the rpoB mutations. This suggests that other changes in transcription associated with the rpoB mutations Figure 3 . Relative mRNA levels of mdtK. Values are shown as the average relative change in total mRNA content (+95% CI) of three biological replicates for the pairs of isogenic strains that represent the evolutionary steps before and after acquisition of the rpoB mutations in the three evolutionary lineages. The broken line represents the expression level of the strain without rpoB mutation. The pairs were gyrA D87G, gyrB S464A, marR D5 nt+rpoB D442 -445 (lineage 1), gyrA D87G, soxR DTpr+rpoB Dup S455 (lineage 2) and gyrA D87G, gyrB S464A, marR D1 nt+rpoB A1277V (lineage 9), and additionally+rpoB H1244L,+rpoB E1272G,+rpoB E1279G,+rpoB Q513K,+rpoB D516N,+rpoB H526L and+rpoB S531F. Ciprofloxacin-selected rpoB mutations are shown in light grey and rifampicin-selected rpoB mutations are shown in dark grey. Ciprofloxacin selects RNA polymerase mutations JAC may be responsible for part of the observed increase in the ciprofloxacin MIC. Given that the comparison of our RNA sequencing data between the two rpoB mutant strains revealed MdtK as the only mutually altered candidate gene with a link to fluoroquinolone resistance, we speculate that additional minor alterations in gene expression levels of a possibly wide array of different genes might result in the observed net increase in the ciprofloxacin MIC for the polymerase mutants.
Next, we asked whether the other ciprofloxacin-selected rpoB mutations located in cluster II (rpoB H1244L, E1272G, A1277V and E1279G) decrease susceptibility to ciprofloxacin by the same mechanism. To test this, we made use of the known evolutionary trajectory of lineage 9 (rpoB A1277V) and used the established genotype prior to the acquisition of rpoB A1277V as the isogenic background for each of the four rpoB mutations found in cluster II. We also included four rifampicin-selected rpoB mutations (Q513K, D516N, H526L and S531F) in this analysis, using the same isogenic backgrounds, to determine whether overexpression of mdtK was specific to ciprofloxacin-selected rpoB mutations. We measured by RT -PCR a 2-to 4-fold up-regulation of the mdtK mRNA level for each of the six ciprofloxacin-selected rpoB mutations, whereas in contrast, three of the four rifampicin-selected rpoB mutations showed no significant increase in mdtK level (Figure 3 ).
Ciprofloxacin-selected rpoB mutations affect MICs of different classes of antibiotic
Because rpoB mutations have pleiotropic effects on transcription (Table S2) , we asked whether the ciprofloxacin-selected mutations might also affect the MIC of other classes of antibiotics used against Gram-negatives. We determined the MIC for isogenic pairs of strains with the evolved resistance genotype as it was prior to, and after, the acquisition of the three different ciprofloxacin-selected rpoB mutations ( Table 5 ). The data show that each of the ciprofloxacin-selected rpoB mutations increased the MIC ( 2-fold) of the fluoroquinolone levofloxacin and of chloramphenicol, ampicillin and trimethoprim. The MIC of fosfomycin was reduced by each of the rpoB mutations, while the MIC of kanamycin and tetracycline was unaffected ( Table 5 ). The increases in MIC observed for the fluoroquinolones, chloramphenicol and trimethoprim are consistent with published data on the effects on MIC of increased MdtK efflux activity with the notable exception of fosfomycin. 28 The increased susceptibility of the rpoB mutants to fosfomycin suggests a different mechanism of action. The conclusion from this experiment is that the ciprofloxacin-selected rpoB mutations can affect the MIC of unrelated classes of antibiotics.
We concluded that the ciprofloxacin-selected rpoB mutations change the global transcription pattern and affect the ciprofloxacin MIC by increasing expression of the MdtK multidrug efflux pump. This increase in drug efflux is responsible for a decreased intracellular concentration of the drug and the observed reduced susceptibility to ciprofloxacin.
Discussion
We have identified a new class of mutation in RNA polymerase that contributes to the evolution of antibiotic resistance by reducing susceptibility to ciprofloxacin. These mutations in rpoB are, with some small phenotypic overlap, distinct from the classical Rif R mutations in rpoB, both in terms of their distinct locations in the gene sequence and protein structure ( Figure 1 ) and in terms of their resistance phenotypes (Table 3) . We have also shown that ciprofloxacin-selected mutations in rpoB confer a competitive growth advantage during evolution of E. coli in the presence of ciprofloxacin.
A feature of the temporal occurrence of the rpoB mutations in these evolution experiments is that in each case they arose after mutations affecting the drug target (DNA gyrase) and drug efflux regulators had already been selected (Table 1 ). This sequential order of occurrence may reflect the different probabilities that each successive class of mutation can satisfy the actual selective conditions. We suggest that mutations in gyrA, although rare, are fixed early in the evolution because they cause a relatively large reduction in susceptibility (8-fold) associated with a very low fitness cost (Figures S1 -S3 ). Mutations in drug efflux regulators that are fixed next occur with a very high frequency (they include knockout mutations), but they cause only a small increase in the MIC (2-fold) and have a modest fitness cost (Figures S1 -S3 ). Mutations in rpoB that are selectively enriched later occur less frequently than efflux regulator mutations (the mutational target is smaller) and cause a similar modest increase in the MIC (2.6-to 4-fold), but have a much larger associated fitness cost (Figure 2) . According to this model, the frequency of occurrence of each mutation, taken together with its net cost/benefit under the actual selective conditions, could explain the relative order of mutation fixation in the evolving strain.
Concerning the mechanism by which these ciprofloxacinselected rpoB mutations reduce susceptibility, we have shown that they increase the transcription of mdtK, encoding a MATE family multidrug transporter that is reported to reduce susceptibility to ciprofloxacin and other fluoroquinolones when overexpressed. 26, 27, 29 These rpoB mutations also affect susceptibility to other unrelated classes of antibiotics, increasing the MIC 2-fold of chloramphenicol, ampicillin and trimethoprim, while increasing susceptibility to fosfomycin ( Table 5 ). The data are consistent with the resistance phenotype being mediated through changes in Pietsch et al.
transcription associated with the ciprofloxacin-selected mutations in rpoB. The data suggest that the ciprofloxacin-selected rpoB mutations act through a common pathway, namely reducing susceptibility to ciprofloxacin by increasing expression of the MdtK efflux pump. The precise mechanism by which the rpoB mutations alter the expression pattern of RNA polymerase is not entirely clear. The mutations cluster in two distinct locations within RNA polymerase and are most likely to alter the function of RNA polymerase in distinct ways. The mutations in cluster I (rpoB D442-445 and Dup S455) are located in the linker region that connects the lobe domain to the rest of the RNA polymerase. The lobe domain is a structure within RNA polymerase that is proposed to form downstream promoter contacts with the DNA during open complex formation. 30 Mutations that alter the length of the linker between the lobe domain and the RNA polymerase are likely to alter the selection of the transcription initiation site. 30 The mutations in cluster II (rpoB H1244L, E1272G, A1277V and E1279G) are all located in the primary channel. It is possible that this region of the RNA polymerase is involved in contact formation to the DNA during open complex formation and that the selected mutations alter promoter specificity.
We note that a fluoroquinolone-resistant clinical isolate of E. coli that lacks any mutations in the drug target genes has been identified in Japan. 31 The resistance phenotype of this strain, HUE1, was shown to be associated with the combined effects of: a plasmid-encoded target protection protein, QnrS; a plasmidencoded efflux pump, OqxAB; the overexpression of several chromosomal efflux pump genes (acrA, acrB, acrE, acrD, mdtK, mdfA and tolC and genes coding for the global activators SoxS, MarA and Rob); and reduced expression of ompF.
32 This is an interesting example of a clinical isolate where increased expression of mdtK contributes to fluoroquinolone resistance, although the cause of the mdtK up-regulation in this strain is not yet known. In Salmonella, transcription of mdtK is positively regulated by RamA, which also controls expression of the AcrAB-TolC pump. 33 However, E. coli lacks a ramA gene 34 and it is currently not known how mdtK expression is normally regulated in E. coli. Our data show that some mutations in rpoB can cause increased expression of mdtK.
Our data are consistent with several earlier reports that have connected RNA polymerase mutants with type II topoisomerase inhibitors. Thus, some rifampicin resistance mutations increase the resistance of E. coli to coumermycin 35 or slightly increase the resistance of Salmonella to the DNA gyrase inhibitors nalidixic acid and novobiocin. 36 No mechanism was ever shown to explain these disparate pieces of data, but they are not inconsistent with the mechanism presented here.
We searched the publicly available WGS data of ciprofloxacinresistant clinical isolates of E. coli 37 -40 for the presence of the ciprofloxacin-selected rpoB mutations identified in this study. Among a total of 215 clinical isolate sequences (214 from the ST131 epidemic clone), we identified 13 SNPs in rpoB and/or rpoC in 12 of the isolates (Table S3) . Each SNP is expected to cause a single amino acid change in RNA polymerase, including three that result in known Rif R mutations. 18 Although none of these 13 SNPs was identical to any of the mutations described in this study, they do show that a variety of amino acid substitution mutations are tolerated in this highly conserved enzyme in clinical isolates of E. coli, including some with a known antibiotic resistance phenotype. Fluoroquinolones are now being increasingly used as second-line drugs for treating MDR Mycobacterium tuberculosis. 41, 42 One of the clinical implications of our data is that the level of susceptibility to fluoroquinolones might already be compromised if some of the rifampicin-resistant mutations in RNA polymerase cause alterations in transcription that reduce susceptibility to these second-line drugs. More generally, our data suggest that the widely appreciated importance of up-regulation of drug efflux as a mechanism of resistance might be due to multiple genetic causes: mutations in genes encoding repressor proteins that regulate pump expression, but also mutations in RNA polymerase with pleiotropic effects on transcription, including up-regulation of efflux pump expression. 
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